UBS Maintains Buy on Akoya Biosciences, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
UBS analyst John Sourbeer maintains a Buy rating on Akoya Biosciences (NASDAQ:AKYA) but lowers the price target from $12 to $7.
October 12, 2023 | 5:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS maintains a Buy rating on Akoya Biosciences but lowers the price target from $12 to $7.
The news is directly related to Akoya Biosciences. While the maintained Buy rating is positive, the lowered price target could have a neutral to slightly negative impact on the stock in the short term as it indicates a lower valuation expectation from the analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100